Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03322566 · ClinicalTrials.gov registry record · Phase 2

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

A Phase 2 study of Lung Cancer, sponsored by Incyte Corporation.

Completed
Registry status
Phase 2
Development phase
233
Enrollment target
20
Study locations

NCT03322566 is a Phase 2 study of Lung Cancer that has completed, run by Incyte Corporation. The registered enrollment target is 233 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03322566, a Phase 2 study of Lung Cancer, has completed, sponsored by Incyte Corporation.

COMPLETED
Registry status
Phase 2
Development phase
233 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in participants with metastatic non-small cell lung cancer (NSCLC).

Conditions Studied

Lung Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG Placebo
  • DRUG Epacadostat
  • DRUG Platinum-based chemotherapy

Study Locations (20)

Florida

  • Lynn Cancer Institute - Boca Raton
  • Florida Cancer Specialists (South Region) - Fort Myers
  • Florida Cancer Specialists (North Region) - St. Petersburg

Arizona

  • Western Regional Medical Center, Inc. - Goodyear
  • Arizona Oncology Associates PC- HOPE - Tucson

Pennsylvania

  • St. Luke's Hospital - Anderson Campus - Easton
  • Allegheny General Hospital - Pittsburgh

Tennessee

  • Tennessee Oncology, PLLC/The Sarah Cannon Research Institute - Chattanooga
  • Tennessee Oncology, PLLC/The Sarah Cannon Research Institute - Nashville

Virginia

  • Oncology & Hematology Assoc. SW Virginia, Inc., DBA Blue Ridge Cancer Care - Blacksburg
  • Emily Couric Clinical Cancer Center - Charlottesville

Alabama

  • Southern Cancer Center, PC - Daphne

Indiana

  • PPG-Oncology - Fort Wayne

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 233 participants
Start Date 2018-01-09
Est. Completion 2020-10-16
Phase Phase 2

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03322566

The ClinicalTrials.gov registry entry for NCT03322566 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 233 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT03322566 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Arizona, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03322566 about?

NCT03322566 is a clinical study titled "A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)". The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in participants with metastatic non-small cell lung cancer (NSCLC).

What is the current status of trial NCT03322566?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 233 participants. The study started on 2018-01-09. Estimated completion is 2020-10-16.

What conditions does trial NCT03322566 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT03322566?

The interventions under investigation include: Pembrolizumab (DRUG), Placebo (DRUG), Epacadostat (DRUG), Platinum-based chemotherapy (DRUG).

Who is sponsoring clinical trial NCT03322566?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03322566 being conducted?

This trial has 20 study locations across Alabama, Arizona, Florida, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.